Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01380899 |
|
Recruitment Status
:
Enrolling by invitation
First Posted
: June 27, 2011
Last Update Posted
: May 4, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
At the beginning of PD is difficult for the clinician to distinguish from Parkinsonism Plus Syndromes (PPS) due to the similarity of symptoms and the lack of specific diagnostic tests.
Specific biomarkers to help improve the accuracy of diagnosis and to separate these two entities are highly needed
The histological hallmark for definite diagnosis of PD is the presence of fibrillar aggregates of phosphorylated alpha-synuclein called Lewy bodies (LBs) and Lewy neurites. Previous autopsy-based studies have revealed that alpha-synuclein is deposited in the peripheral autonomic nervous system including the enteric nervous system of the alimentary tract, cardiac plexus, adrenal medulla and skin.
For this reason, in patients with parkinsonism, an alternative tool could be to demonstrate alpha-synuclein fibrillar aggregates in the skin, allowing early and appropriate diagnosis.
| Condition or disease | Intervention/treatment |
|---|---|
| Parkinson Disease Parkinsonian Disorders | Procedure: Biopsy of skin |
Parkinsonism, the syndrome, is a common movement disorder, and Parkinson's disease, the most common cause of parkinsonism, is the second most prevalent neurodegenerative disease after Alzheimer's disease.
The clinical diagnosis of PD is based on the presence of the four common features: tremor when the limb is at rest, resistance to passive movement of the joints (rigidity), slowness and paucity of movement (bradykinesia and akinesia) and postural abnormalities.
Approximately 25 percent of patients who received an initial clinical diagnosis of PD are found to have parkinsonism as part of another disorder, such as one of the so-called Parkinsonism-Plus Syndromes (PPS) The number and complexity of PPS seem to be increasing. This, along with the lack of diagnostic tests, makes it difficult for the clinician to distinguish between disease types.
Some characteristic clinical features are used for the differential diagnosis, this manifestations include early and severe postural instability, falls in the first year of onset, abnormal eye movements, autonomic dysfunction, cerebellar signs and upper motor neuron signs. The PPS respond poorly to antiparkinsonian medications and have a worse prognosis than does PD. In spite of these suggestive features, not all PD patients have the same progression, in some cases it is impossible to separate typical PD from PPS, especially at the early stage. In this context, biological markers must be of great usefulness for the differential diagnosis of these entities.
Some reports have described early features of PD such as (SPECT) imaging of the dopamine transporter that demonstrated the reduction of dopamine transporter in the striatum body at the early stage of PD and degeneration of the cardiac sympathetic nerve at the beginning of the disease process of PD; this occurs before neuronal cell loss is present in the dorsal vagal nucleus; This fact accounts for reduced cardiac uptake of meta-iodobenzylguanidine (MIBG), a physiological analog of norepinephrine. However, these diagnostic methods are not often performed. Therefore, more sensitive methods are needed to help improve the accuracy of diagnosis of PD.
| Study Type : | Observational |
| Estimated Enrollment : | 23 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Cross-Sectional |
| Official Title: | Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy. |
| Study Start Date : | February 2011 |
| Actual Primary Completion Date : | October 2014 |
| Estimated Study Completion Date : | December 2017 |
| Group/Cohort | Intervention/treatment |
|---|---|
| PD alpha-synuclein |
Procedure: Biopsy of skin
Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
|
| PPS alpha-synuclein |
Procedure: Biopsy of skin
Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
|
- Fraction area of Alpha synuclein expression determined by immunohistochemistry in skin from patients with Parkinson disease and Parkinson Plus Syndromes, as a measure of selectively differentiate these two conditions. [ Time Frame: From date of clinical evaluation until the date of final report, assessed up to six months. ]Alpha synuclein will be analysed by means of immunohistochemistry in skin samples of patients with Parkinson syndrome contrasted to patients with Parkinson Plus Syndromes, as a possible marker to differentiate between them.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years to 95 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Clinical diagnosis of Parkinson's Disease or Parkinson Plus Syndrome
- Subject is a male or female between the age of 50 and 95
- Subject will write the informed consent
Exclusion Criteria:
- History of stroke or/and trauma
- Signs of cerebrovascular pathology
- Brain tumor
- Severe unrelated neurological or physical disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380899
| Mexico | |
| Hospital Central Dr. Ignacio Morones Prieto | |
| San Luis Potosi, Mexico, 78290 | |
| Study Chair: | Ildefonso Rodríguez-Leyva, MD | Hospital Central "Dr. Ignacio Morones Prieto" | |
| Principal Investigator: | Ana A Renteria-Palomo, MD | Universidad Autonoma de San Luis Potosi | |
| Study Director: | Juan P Castanedo-Cazares, MD | Hospital Dr. Ignacio Morones Prieto | |
| Study Director: | Bertha Torres-Alvarez, MD | Hospital Central "Dr. Ignacio Morones Prieto" |
Publications of Results:
Other Publications:
| Responsible Party: | Ildefonso Rodriguez-Leyva, MD, Universidad Autonoma de San Luis Potosí |
| ClinicalTrials.gov Identifier: | NCT01380899 History of Changes |
| Other Study ID Numbers: |
UASLP-PD001 |
| First Posted: | June 27, 2011 Key Record Dates |
| Last Update Posted: | May 4, 2017 |
| Last Verified: | May 2017 |
Keywords provided by Ildefonso Rodriguez-Leyva, Universidad Autonoma de San Luis Potosí:
|
Parkinson Disease Parkinsonian Disorders Lewy Bodies alpha-Synuclein |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |